Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research
Pillser
Search
Sign UpLog In

saccharomyces boulardii

What does the research say about saccharomyces boulardii?

9 health outcomes synthesised

Saccharomyces boulardii, a probiotic yeast, has been studied across 9 health outcomes, primarily for digestive health. The strongest evidence supports its role in reducing diarrhea, with all 9 studies reporting beneficial effects in clinical populations such as patients with H. pylori infection or those on antibiotics. Doses in these studies ranged from 250 mg/day to 500 mg four times daily, with predominantly moderate effect sizes.

Strongest evidence: Two outcomes have high evidence strength. For reducing diarrhea, 9 of 9 studies found benefit (moderate effect), with doses 250 mg/day to 500 mg four times daily. For improving H. pylori eradication rates, 5 of 7 studies showed benefit (small effect), using 250 mg twice daily. Four additional outcomes have moderate evidence: reduced diarrhea rate (8 of 10 beneficial), increased H. pylori eradication (4 of 5), reduced abdominal pain (4 of 5), and reduced diarrhea duration (3 of 4). These show consistent benefits but with smaller effect sizes and some neutral results.

Mixed or weaker evidence: Two outcomes have low evidence: reduced abdominal distension and reduced stool frequency, each with only 3 studies. All reported benefits, but the evidence base is small and conclusions are preliminary.

Effective dose patterns: Most studies used doses around 250–500 mg per day, often split into twice daily dosing. For diarrhea reduction, higher doses up to 500 mg four times daily were used. The median study duration was 14 days across multiple outcomes.

Population insights: The research overwhelmingly focuses on clinical populations: patients with H. pylori infection, children with acute diarrhea, and hospitalized patients on antibiotics. Generalizability to healthy individuals is uncertain. No consistent evidence for elderly or specific deficiency groups.

Notable caveats: Publication bias is a common caveat (null studies less likely published). Many studies did not report dose or supplement form. Effect sizes are generally small to moderate; only constipation and abdominal distension showed large effects, but with few studies.

Frequently asked

  • What is Saccharomyces boulardii good for according to research?
    Research primarily supports its use for reducing diarrhea, with 9 of 9 studies showing benefit (high evidence). It also improves H. pylori eradication rates when combined with standard therapy (5 of 7 studies, high evidence). Other digestive outcomes like abdominal pain and stool frequency show moderate to low evidence.
  • What dose of Saccharomyces boulardii is typically used in studies?
    Doses commonly ranged from 250 mg to 500 mg per day, often split into two or four doses. For diarrhea reduction, doses up to 500 mg four times daily were used. The most frequently reported regimen was 250 mg twice daily for 14 days.
  • Who benefits most from Saccharomyces boulardii?
    The evidence predominantly applies to clinical populations, such as patients with H. pylori infection, children with acute diarrhea, and hospitalized patients on antibiotics. Benefits in healthy individuals are not well studied, so generalizability is limited.
  • Are there caveats or limitations in the research on Saccharomyces boulardii?
    Yes, publication bias is a concern since null results may be underreported. Many studies did not specify the supplement form or duration, limiting dose-form conclusions. Effect sizes are generally small to moderate, and the evidence base for some outcomes is small (only 3 studies).
  • Does Saccharomyces boulardii help with constipation?
    Three studies found large benefits for reducing constipation, all in patients undergoing H. pylori eradication therapy. However, the evidence strength is moderate, and the evidence base is small, so conclusions should be considered preliminary.
  • How strong is the evidence for S. boulardii reducing abdominal pain?
    Four of five studies found benefit, with moderate evidence strength. Effects ranged from small to large, but one neutral meta-analysis introduced some uncertainty. Most studied populations had H. pylori infection.
    Back to top